Evidence map›Paper›PMID 37748715›Full record

ArticleReproductive toxicology (Elmsford, N.Y.)2023

An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.

Yusuke Marikawa, Vernadeth B Alarcon

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reproductive toxicology (Elmsford, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  2. Review
  3. COVID-19 therapeutics.Clinical microbiology reviews · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yusuke MarikawaInstitute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, University of Hawaii John A. Burns School of Medicine, Honolulu, HI 96813, USA.
Vernadeth B AlarconInstitute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, University of Hawaii John A. Burns School of Medicine, Honolulu, HI 96813, USA. Electronic address: vernadet@hawaii.edu.
University of Hawaiʻi at Mānoa · US

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Pallav Pokhrel · 1996 to 2026
$56.2M
Translational Pilot Project ProgramP30GM131944 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI HUI, GEORGE S · 2019 to 2023
$5.9M
Teratogenicity assessment of new antiviral drugs using 3D morphogenesis modelsR03HD110743 · NICHD · UNIVERSITY OF HAWAII AT MANOA · PI MARIKAWA, YUSUKE · 2023 to 2023
$157k
Human pluripotent stem cell-based assessment of dolutegravir teratogenicityR03HD102502 · NICHD · UNIVERSITY OF HAWAII AT MANOA · PI MARIKAWA, YUSUKE · 2020 to 2021
$156k
Regulation of trophectoderm development by mevalonate pathwayR03HD088839 · NICHD · UNIVERSITY OF HAWAII AT MANOA · PI ALARCON, VERNADETH B · 2017 to 2018
$154k
NCI NIH HHS P30 CA071789NICHD NIH HHS R03 HD088839NICHD NIH HHS R03 HD102502NICHD NIH HHS R03 HD110743NIGMS NIH HHS P30 GM131944
6 · The paper itself

Abstract

Molnupiravir is a nucleoside analog antiviral that is authorized for use in the treatment of COVID-19. For its therapeutic action, molnupiravir is converted after ingestion to the active metabolite N

Indexed as

COVID-19NucleosidesAnimalsAntiviral AgentsBlastocystCytidineFemaleHydroxylaminesMicePregnancyAntiviral AgentsCytidineHydroxylaminesmolnupiravirNucleosidesAntiviralBlastocystDevelopmental toxicityIntegrated stress responseMolnupiravirN(4)-hydroxycytidineNucleoside transporterPregnancy

Identifiers

PMID37748715
PMCPMC10671791
OpenAlexW4386987572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.